Gee Eun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gee Eun Lee has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Man-Seong Park
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul 02841, Republic of Korea
4 shared publications - Jin Il Kim
Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul 02841, Republic of Korea
3 shared publications - Joon-Yong Bae
Vaccine Innovation Center-KU Medicine (VIC-K), Seoul 02841, Republic of Korea
3 shared publications - Heedo Park
Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul 02841, Republic of Korea
2 shared publications Joon-Yong Bae
Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul 02841, Republic of Korea
2 shared publicationsJuyoung Cho
Department of Microbiology, Institute for Viral Diseases, Korea University College of Medicine, Seoul 02841, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 4 July 2022
- Published by Elsevier in Cell Reports
- Vol. 40 (3) , 111117
Amelioration of SARS-CoV-2 infection by ANO6 phospholipid scramblase inhibition
- 4 July 2022
- Published by Elsevier in Cell Reports
- Vol. 40 (3) , 111117
Open AccessAmelioration of SARS-CoV-2 infection by ANO6 phospholipid scramblase inhibition
- Open Access
The Immune Correlates of Orthohantavirus Vaccine
Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness.
Open AccessThe Immune Correlates of Orthohantavirus Vaccine
Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness.
- Open Access
- 1 May 2021
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 29 (3) , 268-272
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
Joon-Yong Bae, Gee Eun Lee, Heedo Park, Juyoung Cho, Jeonghun Kim, Jungmin Lee, Kisoon Kim, Jin Il Kim,* and Man-Seong Park,*. Biomolecules & Therapeutics 2021;29:268-72. https://doi.org/10.4062/biomolther.2021.032
- 1 May 2021
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 29 (3) , 268-272
Open AccessAntiviral Efficacy of Pralatrexate against SARS-CoV-2
Joon-Yong Bae, Gee Eun Lee, Heedo Park, Juyoung Cho, Jeonghun Kim, Jungmin Lee, Kisoon Kim, Jin Il Kim,* and Man-Seong Park,*. Biomolecules & Therapeutics 2021;29:268-72. https://doi.org/10.4062/biomolther.2021.032
- Open Access
- 1 January 2021
- Published by XMLink in Yonsei Medical Journal
- Vol. 62 (7) , 584-592
Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
Kim YJ, et al. Yonsei Med J. 2021 Jul;62(7):584-592. https://doi.org/10.3349/ymj.2021.62.7.584
- 1 January 2021
- Published by XMLink in Yonsei Medical Journal
- Vol. 62 (7) , 584-592
Open AccessNeutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19
Kim YJ, et al. Yonsei Med J. 2021 Jul;62(7):584-592. https://doi.org/10.3349/ymj.2021.62.7.584
- Open Access
Pyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza
Since the first human case was reported in Wuhan Province, China in December 2019, SARS-CoV-2 has caused millions of human infections in more than 200 countries worldwide with an approximately 4.01% case-fatality rate (as of 27 July, 2020; based on a WHO situation report), and COVID-19 pandemic has paralyzed our global community. Even though a few candidate drugs, such as remdesivir (a broad antiviral prodrug) and hydroxychloroquine, have been investigated in human clinical trials, their therapeutic efficacy needs to be clarified further to be used to treat COVID-19 patients. Here we show that pyronaridine and artesunate, which are the chemical components of anti-malarial drug Pyramax ® , exhibit antiviral activity against SARS-CoV-2 and influenza viruses. In human lung epithelial (Calu-3) cells, pyronaridine and artesunate were highly effective against SARS-CoV-2 while hydroxychloroquine did not show any effect at concentrations of less than 100 μM. In viral growth kinetics, both pyronaridine and artesunate inhibited the growth of SARS-CoV-2 and seasonal influenza A virus in Calu-3 cells. Taken together, we suggest that artesunate and pyronaridine might be effective drug candidates for use in human patients with COVID-19 and/or influenza, which may co-circulate during this coming winter season.
Open AccessPyronaridine and artesunate are potential antiviral drugs against COVID-19 and influenza
Since the first human case was reported in Wuhan Province, China in December 2019, SARS-CoV-2 has caused millions of human infections in more than 200 countries worldwide with an approximately 4.01% case-fatality rate (as of 27 July, 2020; based on a WHO situation report), and COVID-19 pandemic has paralyzed our global community. Even though a few candidate drugs, such as remdesivir (a broad antiviral prodrug) and hydroxychloroquine, have been investigated in human clinical trials, their therapeutic efficacy needs to be clarified further to be used to treat COVID-19 patients. Here we show that pyronaridine and artesunate, which are the chemical components of anti-malarial drug Pyramax ® , exhibit antiviral activity against SARS-CoV-2 and influenza viruses. In human lung epithelial (Calu-3) cells, pyronaridine and artesunate were highly effective against SARS-CoV-2 while hydroxychloroquine did not show any effect at concentrations of less than 100 μM. In viral growth kinetics, both pyronaridine and artesunate inhibited the growth of SARS-CoV-2 and seasonal influenza A virus in Calu-3 cells. Taken together, we suggest that artesunate and pyronaridine might be effective drug candidates for use in human patients with COVID-19 and/or influenza, which may co-circulate during this coming winter season.